Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X

Find the latest Drugs in Development and Pipeline Prospector News of Ketabon.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Ketabon
Germany Flag
Country
Country
Germany
Address
Address
Wilhelm-Wagenfeld-Straße 20 D-80807 München
Telephone
Telephone
+49 15123146187
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

KET01 is an oral prolonged-release ketamine formulation, a rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia typically in combination with a muscle relaxant. It is being currently developed for treatment-resistant depression.


Lead Product(s): Ketamine Hydrochloride

Therapeutic Area: Psychiatry/Psychology Product Name: KET01

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 13, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY